COPENHAGEN, Denmark, Nov. 11, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced plans to present at an upcoming investor conference.
| Event: |
2015 Stifel Healthcare Conference |
| Location: |
New York Palace Hotel, New York, NY |
| Date: |
Wednesday, November 18, 2015 |
| Time: |
8:45am EST |
An audio webcast of this event will be posted to the Investor Relations section of the Ascendis Pharma website at www.ascendispharma.com, and will be available until December 31, 2015.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of therapeutics with bestinclass profiles that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.
The Ascendis Pharma pipeline includes TransCon Growth Hormone, a proprietary program that has completed Phase 2 studies in adults and children with growth hormone deficiency. Ascendis Pharma expects to initiate a Phase 3 pediatric study of TransCon Growth Hormone in mid-2016. Ascendis Pharma is also developing its wholly-owned TransCon Treprostinil for the treatment of pulmonary arterial hypertension. In addition to its proprietary programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its collaboration partners. These collaborations are with Sanofi in diabetes and Genentech in the field of ophthalmology.
Investor contact:
Martin Auster, M.D.
Chief Business Officer
(650) 617-3403
[email protected]
Logo - http://photos.prnewswire.com/prnh/20150824/260617LOGO
SOURCE Ascendis Pharma A/S
Share this article